Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors, Part B, Volume 172 in the International Review of Neurobiology series, includes chapters on Spinal cord injury induced exacerbation of Alzheimer's disease pathophysiology in the cord is reduced by topical application of nanowired cerebrolysin and antibodies to tumor necrosis factor alpha, Nanodelivery of histamine H3 receptor inverse agonist BF-2549 with clobenpropit a H3 receptor antagonist and H4 receptor agonist induced neuroprotection in spinal cord injury is potentiated by antioxidant compound H-290/51, and Neuromodulation and quality of life for patient with spasticity after spinal cord injury, and more.Other sections cover Efficacy of invasive and non-invasive methods for the treatment of Parkinson´s disease: nanodelivery and enriched environment, Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with brain injury, Nicotine Neurotoxicity Exacerbation following Engineered Ag and Cu (50-60 nm) nanoparticles intoxication, and Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron. Provides the authority and expertise of leading contributors from an international board of authorsPresents the latest release in International Review on Neurobiology seriesUpdated release includes the latest information on Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors INDICE: Section I: Spinal cord Injury1. Spinal cord injury induced exacerbation of Alzheimer's disease pathophysiology in the cord is reduced by topical application of nanowired cerebrolysin and antibodies to tumor necrosis factor alphaAruna Sharma2. Nanodelivery of histamine H3 receptor inverse agonist BF-2549 with clobenpropit a H3 receptor antagonist and H4 receptor agonist induced neuroprotection in spinal cord injury is potentiated by antioxidant compound H-290/51Anca Dana Buzoianu3. Neuromodulation and quality of life for patient with spasticity after spinal cord injuryArtur BiktimirovSection II : Neurodegenerative disease4. Efficacy of invasive and non-invasive methods for the treatment of Parkinson´s disease: nanodelivery and enriched environmentAndreas Vaquero5. Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with brain injuryZhenguo G WangSection III Drugs of Abuse and Neurotoxicity6. Nicotine Neurotoxicity Exacerbation following Engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetronZ Ryan TianSection IV: Clinical Neurology and Oncology7. The technology of genomic balancing the hemopoiesis precursor clones by nucleosome monomers of human genomic DNA (hDNAnmr) and perspectives of clinical useAndrey Bryukhovetskiy8. An overview of Twist1 in glioma progression and recurrence;Zhiqiang Zhang9. A review of traditional Chinese medicine Curcumae Rhizoma for treatment of glioma.Cong Li10. A case of a large lumbar schwannoma from a filum terminal and literature review.Chao He

• ISBN: 978-0-443-29468-6
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Páginas: 356
• Fecha Publicación: 11/10/2023
• Nº Volúmenes: 1
• Idioma: Inglés